Glaxo Fined $54.3 Million in `Pay-for-Delay' Antitrust Probe

  • U.K. antitrust regulator says deals blocked generic drugs
  • Generic drug makers are also fined for 2001-2004 deals

GlaxoSmithKline Plc was fined 37.6 million pounds ($54.3 million) by the U.K.’s antitrust watchdog over pay-for-delay deals that held back sales of cheaper, generic versions of its anti-depressant Seroxat.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.